You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at S&P Capital IQ Pro or S&P Capital IQ .
BioPharmX receives non-compliance notice from NYSE
S&P Capital IQ Pro | Unrivaled Sector Coverage
S&P Capital IQ Pro | Powering Your Edge
Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud
Investment Research Analysts Providing Greater Coverage on Inflation
BioPharmX Corp. received a non-compliance notice from the NYSE American LLC on Dec. 1 because its common stock was selling for a low price per share for a substantial period of time.
The company has until June 1, 2018 to effect a reverse stock split or show a sustained price improvement to remain listed on the exchange.
The notice doesn't have an immediate effect on BioPharmX's shares and they will continue trading until the given period.